Search PubMed⌕ Search

Biomedical subjects

A Das Gupta

Publications and source records attributed to A Das Gupta.

At least 37 records · Page 2Linked to original sources
PubMed1984

GM 58/8: a monoclonal antibody that identifies a new lineage-specific determinant expressed by myeloid progenitors (CFU-GM) and their progeny.

A cytotoxic (IgM) monoclonal antibody (McAb) raised against human erythroleukaemia cell line HEL appears specific for the myelomonocytic lineage. Indirect immunofluorescence and fluorescence-activated cell sorter analyses of peripheral blood and bone marrow cells showed that this McAb (designated GM 58/8) reacts exclusively with more than 90% of the granulocytes, monocytes and myeloid precursors. The positive (fluorescent) fraction sorted from McAb-treated bone marrow buffy coat cells showed a marked enrichment of myeloid precursors, while nonmyeloid cells were recovered in the negative fraction. GM 58/8 specifically inhibited the growth of 90-100% of the committed myelomonocytic progenitors (CFU-GM) in five complement-mediated cytotoxicity experiments. GM 58/8 had virtually no effect on the erythroid progenitor (BFU-E and CFU-E) growth. Cell sorting experiments using this McAb resulted in recovery of 84% of CFU-GM among the fluorescent fractions. Comparisons with other anti-myelomonocytic McAbs reported so far suggest that GM 58/8 has more restricted reactivity and shows more efficient CFU-GM cytotoxicity. Patterns of reactivity with normal cells and established lines indicate that the antigenic determinant identified by GM 58/8 is different from that recognized by previously described anti-myelomonocytic McAbs. McAb GM 58/8 could be used to isolate or remove pure populations of progenitors and/or more differentiated cells of the myelomonocytic lineage for in vitro studies. This study also provides evidence that the HEL cell line, derived originally from an erythroleukaemia patient, expresses an antigenic determinant shared by the normal cells of myelomonocytic lineage.

Antibodies, Monoclonal↗
PubMed1980

Associated red cell enzyme deficiencies and their significance in a case of congenital enzymopenic methemoglobinemia.

Examination of the red cell enzyme profile in a case of congenital methemoglobinemia has shown associated deficiencies of glutathione reductase (GR) and glutathione peroxidase (GSHPx) in addition to NADH-methemoglobin reductase deficiency. Contrary to expectations, GR and GSHPx deficiencies do not seem to have contributed to the methemoglobinemia in this case. The lack of symptoms in spite of a high methemoglobin (Hi) level (35%) appears to be due to the restriction of Hi to a small percentage of red cells.

Adult↗
PubMed1971

Motor neurone disease.

Explore the source record for details and available documents.

Amyotrophic Lateral Sclerosis↗
PubMed1967

Myopathies.

Explore the source record for details and available documents.

Child↗
PubMed1967

Controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in Calcutta.

To assess the effectiveness of cholera vaccines, 2 controlled field trials were made in Calcutta-an endemic area-during 1964 and 1965. Three Indian vaccines of which 1 was grown on casein hydrolysate and 2 on agar, a freeze-dried vaccine from the Walter Reed Army Institute of Research (WRAIR), Washington, D.C., and an El Tor vaccine from the Philippines were used, with typhoid-paratyphoid (TAB) vaccine as a control. The 210 112 volunteers were vaccinated subcutaneously with a single dose of one of the vaccines.In the 1964 trial, the number of bacteriologically confirmed cases was not enough to show statistically significant differences in incidence between the 5 vaccine groups and the control group. However, the WRAIR freeze-dried vaccine protected about 40% of the vaccinees for 6 months after vaccination, although the efficacy was higher (57%) during the first 3 months than during the subsequent 3 months (28%). Agar-grown vaccine, produced by the Central Research Institute, Kasauli, was 37% efficacious.In the 1965 trial, owing to the small number of cases in the study area, the Kasauli vaccine was the only one to show statistically significant protection (40%).

Adolescent↗